(Q37282280)

19 August 2017

1 reference

title

Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer (English)

1 reference

adaptive radiation therapy

19 August 2017

main subject

0 references

1 reference

1 reference

Mark D Hurwitz

1

1 reference

19 August 2017

language of work or name

1 reference

30 September 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

668-676

1 reference

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

Combined modality treatment in the management of high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

Retropubic Implantation of Iodine 125 in the Treatment of Prostatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

High dose rate brachytherapy as a boost for the treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Rectal fistulas after prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Prediction of urinary symptoms after 125iodine prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1224

7 January 2021

Identifiers

DOI

10.1038/NCPONC1224

1 reference

19 August 2017

1 reference